Ulcerative Colitis

Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print

Volumn , Issue , 2010, Pages 1975-2013

  Osterman, Mark T ^a,b   Lichtenstein, Gary R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863552124     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6189-2.00112-8     Document Type: Chapter

References (460)

1. Cho JH The genetics and immunopathogenesis of inflammatory bowel disease Nature Rev Immunol 8 2008 458(Ref 29.)
2. Duerr RH., Taylor KD., Brant SR., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene Science 314 2006 1461(Ref 33.)
3. Fleshner P., Ippoliti A., Dubinsky M., et al. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis Clin Gastroenterol Hepatol 5 2007 952(Ref 394.)
4. Frank DN., St. Amand AL., Feldman RA., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases Proc Natl Acad Sci U S A 104 2007 13780(Ref 43.)
5. Hahnloser D., Pemberton JH., Wolff BG., et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis Br J Surg 94 2007 333(Ref 315.)
6. Kandiel A., Fraser AG., Korelitz BI., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine Gut 54 2005 1121(Ref 221.)
7. Lichtiger S., Present DH., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 330 1994 1841(Ref 223.)
8. Loftus EV Jr Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences Gastroenterology 126 2004 1504(Ref 5.)
9. Moskovitz DN., Van Assche G., Maenhout B., et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis Clin Gastroenterol Hepatol 4 2006 760(Ref 227.)
10. Rubin PH., Friedman S., Harpaz N., et al. Colonoscopic polypectomy in chronic colitis: Conservative management after endoscopic resection of dysplastic polyps Gastroenterology 117 1999 1295(Ref 352.)
11. Rutgeerts P., Sandborn WJ., Feagan BG., et al. Infliximab for induction and maintenance therapy for ulcerative colitis N Engl Med J 353 2005 2462(Ref 290.)
12. Sartor RB Microbial influences in inflammatory bowel diseases Gastroenterology 134 2008 577(Ref 44.)
13. Shih DQ., Targan SR Immunopathogenesis of inflammatory bowel disease World J Gastroenterol 14 2008 390(Ref 67.)
14. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; (2):CD000543. (Ref 140.)
15. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; (2):CD000544. (Ref 151.)
16. Wilks S Lectures on pathological anatomy 1859 Ongman, Brown, Green, Longman, & Roberts London.
17. Wilks S. Morbid appearances in the intestines of Miss Bankes. Med Times Gazette 1859, p 264.
18. Hawkins HP An address on the natural history of ulcerative colitis and its bearing on treatment Br Med J 1 1909 765-770.
19. Hurst AF Ulcerative colitis Guy Hosp Rep 71 1909 26.
20. Loftus EV Jr Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences Gastroenterology 126 2004 1504.
21. Shivananda S., Lennard-Jones J., Logan R., et al. Incidence of inflammatory bowel disease across Europe: Is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD) Gut 39 1996 690.
22. Sandler RS., Loftus EV Epidemiology of inflammatory bowel diseases In: Sartor RB., Sandborn WJ Kirsner’s inflammatory bowel diseases6th ed 2004 WB Saunders Philadelphia 245.
23. Calkins BM., Lilienfeld AM., Garland CF., et al. Trends in incidence rates of ulcerative colitis and Crohn’s disease Dig Dis Sci 29 1984 913.
24. Hiatt RA., Kaufman L Epidemiology of inflammatory bowel disease in a defined northern California population West J Med 149 1988 541.
25. Wright JP., Froggatt J., O’Keefe EA., et al. The epidemiology of inflammatory bowel disease in Cape Town 1980-1984 S Afr Med J 70 1986 10.
26. Yoshida Y., Murata Y Inflammatory bowel disease in Japan: Studies of epidemiology and etiopathogenesis Med Clin North Am 74 1990 67.
27. Lee YM., Fock K., See SJ., et al. Racial differences in the prevalence of ulcerative colitis and Crohn’s disease in Singapore J Gastroenterol Hepatol 15 2000 622.
28. Yang SK., Hong WS., Min YI., et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997 J Gastroenterol Hepatol 15 2000 1037.
29. Probert CS., Jayanthi V., Rampton DS., et al. Epidemiology of inflammatory bowel disease in different ethnic and religious groups: Limitations and aetiological clues Int J Colorectal Dis 11 1996 25.
30. Probert CS., Jayanthi V., Pinder D., et al. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire Gut 33 1992 687.
31. Carr I., Mayberry JF The effects of migration on ulcerative colitis: A three-year prospective study among Europeans and first-and second-generation South Asians in Leicester (1991-1994) Am J Gastroenterol 94 1999 2918.
32. Satsangi J., Jewell DP., Rosenberg WM., et al. Genetics of inflammatory bowel disease Gut 35 1994 696.
33. Orholm M., Binder V., Sorensen TI., et al. Concordance of inflammatory bowel disease among Danish twins: Results of a nationwide study Scand J Gastroenterol 35 2000 1075.
34. Thompson NP., Driscoll R., Pounder RE., et al. Genetics versus environment in inflammatory bowel disease: Results of a British twin study BMJ 312 1996 95.
35. Tysk C., Lindberg E., Jarnerot G., et al. Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins: A study of heritability and the influence of smoking Gut 29 1988 990.
36. Yang H., McElree C., Roth MP., et al. Familial empirical risks for inflammatory bowel disease: Differences between Jews and non-Jews Gut 34 1993 517.
37. Laharie D., Debeugny S., Peeters M., et al. Inflammatory bowel disease in spouses and their offspring Gastroenterology 120 2001 816.
38. Satsangi J., Grootscholten C., Holt H., et al. Clinical patterns of familial inflammatory bowel disease Gut 38 1996 738.
39. Binder V Genetic epidemiology in inflammatory bowel disease Digest Dis 16 1998 351.
40. Lee JC., Lennard-Jones JE Inflammatory bowel disease in 67 families each with three or more affected first-degree relatives Gastroenterology 111 1996 587.
41. Satsangi J., Parkes M., Louis E., et al. Two-stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7, and 12 Nature Genet 14 1996 199.
42. van Heel DA., Satsangi J., Carey AH., et al. Inflammatory bowel disease: Progress toward a gene Can J Gastroenterol 14 2000 207.
43. Parkes M., Barmada MM., Satsangi J., et al. The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease Am J Hum Genet 67 2000 1605.
44. Cho JH The genetics and immunopathogenesis of inflammatory bowel disease Nature Rev Immunol 8 2008 458.
45. Pierik M., Joossens M., Henckaerts L., et al. Mixed IBD families: A distinct entity with IBD Gastroenterology 130 2006 A357.
46. Schwab M., Schaeffeler E., Marx C., et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis Gastroenterology 124 2003 26.
47. Fisher SA., Tremelling M., Anderson CA., et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn’s disease Nature Genet 40 2008 710.
48. Duerr RH., Taylor KD., Brant SR., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene Science 314 2006 1461.
49. D’Haens GR., Geboes K., Peeters M., et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum Gastroenterology 114 1998 262.
50. Taurog JD., Richardson JA., Croft JT., et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats J Exp Med 180 1994 2359.
51. Rath HC., Herfarth HH., Ikeda JS., et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis J Clin Invest 98 1996 945.
52. Sellon RK., Tonkonogy S., Schultz M., et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice Infect Immun 66 1998 5224.
53. Veltkamp C., Tonkonogy SL., de Jong YP., et al. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(e26) mice Gastroenterology 120 2001 900.
54. Sartor RB Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics Gastroenterology 126 2004 1620.
55. Sheil B., Shanahan F., O’Mahony L Probiotic effects on inflammatory bowel disease J Nutr 137 2007 S819.
56. Ley RE., Turnbaugh PJ., Klein S., et al. Microbial ecology: Human gut microbes associated with obesity Nature 444 2006 1022.
57. Eckburg PB., Bik EM., Bernstein CN., et al. Diversity of the human intestinal microbial flora Science 308 2005 1635.
58. Frank DN., St. Amand AL., Feldman RA., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases Proc Natl Acad Sci U S A 104 2007 13780.
59. Sartor RB Microbial influences in inflammatory bowel diseases Gastroenterology 134 2008 577.
60. Boyko EJ., Perera DR., Koepsell TD., et al. Effects of cigarette smoking on the clinical course of ulcerative colitis Scand J Gastroenterol 23 1988 1147.
61. Lindberg E., Tysk C., Andersson K., et al. Smoking and inflammatory bowel disease: A case control study Gut 29 1988 352.
62. Merrett MN., Mortensen N., Kettlewell M., et al. Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis Gut 38 1996 362.
63. Jones DT., Osterman MT., Bewtra M., et al. Passive smoking and inflammatory bowel disease: A meta-analysis Am J Gastroenterol 103 9 2008 2382-2393.
64. Rutgeerts P., D’Haens G., Hiele M., et al. Appendectomy protects against ulcerative colitis Gastroenterology 106 1994 1251.
65. Andersson RE., Olaison G., Tysk C., et al. Appendectomy and protection against ulcerative colitis N Engl J Med 344 2001 808.
66. Kett K., Rognum TO., Brandtzaeg P Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn’s disease of the colon Gastroenterology 93 1987 919.
67. Scott MG., Nahm MH., Macke K., et al. Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: Differences between ulcerative colitis, Crohn’s disease, and controls Clin Exp Immunol 66 1986 209.
68. Aronson RA., Cook SL., Roche JK Sensitization to epithelial antigens in chronic mucosal inflammatory disease: I. Purification, characterization, and immune reactivity of murine epithelial cell-associated components (ECAC) J Immunol 131 1983 2796.
69. Snook JA., de Silva HJ., Jewell DP The association of auto-immune disorders with inflammatory bowel disease Q J Med 72 1989 835.
70. Das KM., Dasgupta A., Mandal A., et al. Autoimmunity to cytoskeletal protein tropomyosin: A clue to the pathogenetic mechanism for ulcerative colitis J Immunol 150 1993 2487.
71. Saxon A., Shanahan F., Landers C., et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease J Allergy Clin Immunol 86 1990 202.
72. Seibold F., Slametschka D., Gregor M., et al. Neutrophil autoantibodies: A genetic marker in primary sclerosing cholangitis and ulcerative colitis Gastroenterology 107 1994 532.
73. Shanahan F Neutrophil autoantibodies in inflammatory bowel disease: Are they important? Gastroenterology 107 1994 586.
74. Terjung B., Spengler U., Sauerbruch T., et al. “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines Gastroenterology 119 2000 310.
75. Vecchi M., Bianchi MB., Sinico RA., et al. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: Sensitivity, specificity, and recognition of putative antigens Digestion 55 1994 34.
76. Sandborn WJ., Landers CJ., Tremaine WJ., et al. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis Am J Gastroenterol 90 1995 740.
77. Fleshner PR., Vasilauskas EA., Kam LY., et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis Gut 49 2001 671.
78. Vasiliauskas EA., Kam LY., Karp LC., et al. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics Gut 47 2000 487.
79. Targan SR., Landers CJ., Yang H., et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease Gastroenterology 128 2005 2020.
80. Fleshner P., Ippoliti A., Dubinsky M., et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis Clin Gastroenterol Hepatol 6 2008 561.
81. Mei L., Targan SR., Landers CJ., et al. Familial expression of anti-Escherichia coli outer membrane protein C in relatives of patients with Crohn’s disease Gastroenterology 130 2006 1078.
82. Shih DQ., Targan SR Immunopathogenesis of inflammatory bowel disease World J Gastroenterol 14 2008 390.
83. 4-integrins in lymphocyte homing to mucosal tissues in vivo J Immunol 152 1994 3282.
84. Senju M., Wu KC., Mahida YR., et al. Two-color immunofluorescence and flow cytometric analysis of lamina propria lymphocyte subsets in ulcerative colitis and Crohn’s disease Dig Dis Sci 36 1991 1453.
85. Raedler A., Fraenkel S., Klose G., et al. Elevated numbers of peripheral T cells in inflammatory bowel diseases displaying T9 antigen and Fc alpha receptors Clin Exp Immunol 60 1985 518.
86. Duchmann R., Strober W., Alling DW., et al. T-cell receptor Vβ gene expression in inflammatory bowel disease lamina propria lymphocytes: Evidence for altered Vβ gene usage Inflamm Bowel Dis 1 1995 184.
87. Meuret G., Bitzi A., Hammer B Macrophage turnover in Crohn’s disease and ulcerative colitis Gastroenterology 74 1978 501.
88. Mayer L., Shlien R Evidence for function of Ia molecules on gut epithelial cells in man J Exp Med 166 1987 1471.
89. Reinecker HC., Podolsky DK Human intestinal epithelial cells express functional cytokine receptors sharing the common gamma c chain of the interleukin-2 receptor Proc Natl Acad Sci U S A 92 1995 8353.
90. Watanabe M., Ueno Y., Yajima T., et al. Interleukin-7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes J Clin Invest 95 1995 2945.
91. Jung HC., Eckmann L., Yang SK., et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion J Clin Invest 95 1995 55.
92. Huang GT., Eckmann L., Savidge TC., et al. Infection of human intestinal epithelial cells with invasive bacteria upregulates apical intercellular adhesion molecule-1 (ICAM)-1) expression and neutrophil adhesion J Clin Invest 98 1996 572.
93. Allan A., Bristol JB., Williamson RC Crypt cell production rate in ulcerative proctocolitis: Differential increments in remission and relapse Gut 26 1985 999.
94. Gibson PR., van de Pol E., Barratt PJ., Doe WF Ulcerative colitis-a disease characterised by the abnormal colonic epithelial cell? Gut 29 1988 516-521.
95. Podolsky DK., Isselbacher KJ Glycoprotein composition of colonic mucosa: Specific alterations in ulcerative colitis Gastroenterology 87 1984 991.
96. Pullan RD., Thomas GA., Rhodes M., et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis Gut 35 1994 353.
97. Schultsz C., Van Den Berg FM., Ten Kate FW., et al. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls Gastroenterology 117 1999 1089.
98. Kleessen B., Kroesen AJ., Buhr HJ., et al. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls Scand J Gastroenterol 37 2002 1034.
99. Swidsinski A., Ladhoff A., Pernthaler A., et al. Mucosal flora in inflammatory bowel disease Gastroenterology 122 2002 44.
100. Hermiston ML., Gordon JI Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin Science 270 1995 1203.
101. Powrie F., Coffman RL Cytokine regulation of T-cell function: Potential for therapeutic intervention Immunol Today 14 1993 270.
102. Smith KM., Eaton AD., Finlayson LM., et al. Oral tolerance Am J Respir Crit Care Med 162 2000 S175.
103. Kronenberg M., Gapin L The unconventional lifestyle of NK T cells Nature Rev Immunol 2 2002 557.
104. Fuss IJ., Heller F., Boirivant M., et al. Nonclassical CD1d-restricted NK T cells produce IL-13 characterize an atypical Th2 response in ulcerative colitis J Clin Invest 113 2004 1490.
105. Kolls JK., Linden A Interleukin-17 family members and inflammation Immunity 21 2004 467.
106. Palmer MT., Weaver CT Narcissistic helpers Nature 448 2007 416.
107. Wiekowski MT., Leach MW., Evans EW., et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death J Immunol 166 2001 7563.
108. Elson CO., Cong Y., Weaver CT., et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice Gastroenterology 132 2007 2359.
109. Boughton-Smith N., Pettipher R Lipid mediators and cytokines in inflammatory bowel disease Eur J Gastroenterol Hepatol 2 1990 241.
110. Drossman DA., Ringel Y Psychosocial factors in ulcerative colitis and Crohn’s disease In: Sartor RB., Sandborn WJ Kirsner’s inflammatory bowel diseases6th ed 2004 WB Saunders Philadelphia 340.
111. Levenstein S., Prantera C., Varvo V., et al. Stress and exacerbation in ulcerative colitis: A prospective study of patients enrolled in remission Am J Gastroenterol 95 2000 1213.
112. Bitton A., Sewitch MJ., Peppercorn MA., et al. Psychosocial determinants of relapse in ulcerative colitis: A longitudinal study Am J Gastroenterol 98 2003 2203.
113. Langholz E., Munkholm P., Davidsen M., et al. Course of ulcerative colitis: Analysis of changes in disease activity over years Gastroenterology 107 1994 3.
114. D’Haens G., Geboes K., Peeters M., et al. Patchy cecal inflammation associated with distal ulcerative colitis: A prospective endoscopic study Am J Gastroenterol 92 1997 1275.
115. Surawicz CM., Belic L Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease Gastroenterology 86 1984 104.
116. Allison MC., Hamilton-Dutoit SJ., Dhillon AP., et al. The value of rectal biopsy in distinguishing self-limited colitis from early inflammatory bowel disease Q J Med 65 1987 985.
117. Both H., Torp-Pedersen K., Kreiner S., et al. Clinical appearance at diagnosis of ulcerative colitis and Crohn’s disease in a regional patient group Scand J Gastroenterol 18 1983 987.
118. Pimentel M., Chang M., Chow EJ., et al. Identification of a prodromal period in Crohn’s disease but not ulcerative colitis Am J Gastroenterol 95 2000 3458.
119. Rao SS., Holdsworth CD., Read NW Symptoms and stool patterns in patients with ulcerative colitis Gut 29 1988 342.
120. Sandle GI., Higgs N., Crowe P., et al. Cellular basis for defective electrolyte transport in inflamed human colon Gastroenterology 99 1990 97.
121. Rao SS., Read NW., Davison PA., et al. Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis Gastroenterology 93 1987 1270.
122. Rao SS., Read NW., Brown C., et al. Studies on the mechanism of bowel disturbance in ulcerative colitis Gastroenterology 93 1987 934.
123. Sinclair TS., Brunt PW., Mowat NA Nonspecific proctocolitis in northeastern Scotland: A community study Gastroenterology 85 1983 1.
124. Edwards FC., Truelove SC The course and prognosis of ulcerative colitis Gut 41 1963 299.
125. Hendriksen C., Kreiner S., Binder V Long-term prognosis in ulcerative colitis-based on results from a regional patient group from the county of Copenhagen Gut 26 1985 158.
126. Stonnington CM., Phillips SF., Zinsmeister AR., et al. Prognosis of chronic ulcerative colitis in a community Gut 28 1987 1261.
127. Ayres RC., Gillen CD., Walmsley RS., et al. Progression of ulcerative proctosigmoiditis: Incidence and factors influencing progression Eur J Gastroenterol Hepatol 8 1996 555.
128. Powell-Tuck J., Ritchie JK., Lennard-Jones JE The prognosis of idiopathic proctitis Scand J Gastroenterol 12 1977 727.
129. Hoie L., Wolters FL., Riis L., et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years Gastroenterology 132 2007 507.
130. Hendriksen C., Binder V Social prognosis in patients with ulcerative colitis BMJ 281 1980 581.
131. Ritchie JK., Powell-Tuck J., Lennard-Jones JE Clinical outcome of the first ten years of ulcerative colitis and proctitis Lancet 1 1978 1140.
132. Brostrom O., Monsen U., Nordenwall B., et al. Prognosis and mortality of ulcerative colitis in Stockholm County, 1955-1979 Scand J Gastroenterol 22 1987 907.
133. Card T., Hubbard R., Logan RF Mortality in inflammatory bowel disease: A population-based cohort study Gastroenterology 125 2003 1583.
134. Winther KV., Jess T., Langholz E., et al. Survival and cause-specific mortality in ulcerative colitis: Follow-up of a population-based cohort in Copenhagen County Gastroenterology 125 2003 1576.
135. Pera A., Bellando P., Caldera D., et al. Colonoscopy in inflammatory bowel disease: Diagnostic accuracy and proposal of an endoscopic score Gastroenterology 92 1987 181.
136. Nguyen GC., Kaplan G., Harris ML., et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients Am J Gastroenterol 103 2008 1443.
137. Mylonaki M., Langmead L., Pantes A., et al. Enteric infection in relapse of inflammatory bowel disease: Importance of microbiological examination of stool Eur J Gastroenterol Hepatol 16 2004 775.
138. Pfau P., Kochman ML., Furth EE., et al. Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient Am J Gastroenterol 96 2001 895.
139. Truelove SC., Witts LJ Cortisone in ulcerative colitis: Final report on a therapeutic trial BMJ 2 1955 1041.
140. Sutherland LR., Martin F., Greer S., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis Gastroenterology 92 1987 1894.
141. Schroeder KW., Tremaine WJ., Ilstrup DM Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study N Engl J Med 317 1987 1625.
142. Baron JH., Connell AM., Lennard-Jones JE Variation between observers in describing mucosal appearances in proctocolitis BMJ 5375 1964 89.
143. Truelove SC., Richards WC Biopsy studies in ulcerative colitis BMJ 4979 1956 1315.
144. Hrobjartsson A., Gotzsche P Is the placebo powerless? N Engl J Med 344 2001 1594.
145. Su C., Lewis JD., Goldberg B., et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis Gastroenterology 132 2007 516.
146. Baron JH., Connell AM., Lennard-Jones JE Sulphasalazine and salicylazosulphadimidine in ulcerative colitis Lancet 1 1962 1094.
147. Svartz N Salazopyrin, a new sulfanilamide preparation Acta Med Scand 110 1942 577.
148. Azad Khan AK., Piris J., Truelove SC An experiment to determine the active therapeutic moiety of sulphasalazine Lancet 2 1977 892.
149. Van Hees PA., Bakker JH., van Tongeren JH Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study to determine the active therapeutic moiety of sulfasalazine Gut 21 1980 632.
150. Dick AP., Grayson MJ., Carpenter RG., et al. Controlled trial of sulphasalazine in the treatment of ulcerative colitis Gut 5 1964 437.
151. Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev 2000; CD000543.
152. Sutherland LR., May GR., Shaffer EA Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis Ann Intern Med 118 1993 540.
153. Meyers S., Sachar DB., Present DH., et al. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial Gastroenterology 93 1987 1255.
154. Sninsky CA., Cort DH., Shanahan F., et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: A multicenter study Ann Intern Med 115 1991 350.
155. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev2006; CD000543.
156. Kamm MA., Sandborn WJ., Gassull M., et al. Once-daily, high-concentration MMX mesalamine in active ulcerative Gastroenterology 132 2007 66.
157. Lichtenstein GR., Kamm MA., Boddu P., et al. Effect of once-or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis Clin Gastroenterol Hepatol 5 2007 95.
158. Green JR., Lobo AJ., Holdsworth CD., et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group Gastroenterology 114 1998 15.
159. Pruitt R., Hanson J., Safdi M., et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis Am J Gastroenterol 97 2002 3078.
160. Hanauer SB., Sandborn WJ., Dallaire C., et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial Can J Gastroenterol 21 2007 827.
161. Hanauer SB., Sandborn WJ., Kornbluth A., et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial Am J Gastroenterol 100 2005 2478.
162. Azad Khan AK., Howes DT., Piris J., et al. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis Gut 21 1980 232.
163. Misiewicz JJ., Lond MB Controlled trial of sulphasalazine in maintenance treatment of ulcerative colitis Lancet 2 1965 185.
164. Kiilerich S., Ladefoged K., Rannem T., et al. Prophylactic effects of olsalazine versus sulphasalazine during 12 months’ maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group Gut 33 1992 252.
165. Hanauer S., Schwartz J., Robinson M., et al. Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial. Pentasa Study Group Am J Gastroenterol 88 1993 1188.
166. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; CD000544.
167. Kruis W., Schreiber S., Theuer D., et al. Low-dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high-dose balsalazide (3.0 g twice daily) was superior in preventing relapses Gut 49 2001 783.
168. Giaffer MH., O’Brien CJ., Holdsworth CD Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine Aliment Pharmacol Ther 6 1992 51.
169. Mansfield JC., Giaffer MH., Cann PA., et al. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis Aliment Pharmacol Ther 16 2002 69.
170. Loftus EV Jr., Kane SV., Bjorkman D Systematic review: Short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis Aliment Pharmacol Ther 19 2004 179.
171. Marshall JK., Irvine EJ Rectal aminosalicylate therapy for distal ulcerative colitis: A meta-analysis Aliment Pharmacol Ther 9 1995 293.
172. Cohen RD., Woseth DM., Thisted RA., et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis Am J Gastroenterol 95 2000 1263.
173. Kam L., Cohen H., Dooley C., et al. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults Am J Gastroenterol 91 1996 1338.
174. Campieri M., Gionchetti P., Belluzzi A., et al. Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis Dig Dis Sci 32 1987 67S.
175. Safdi M., DeMicco M., Sninsky C., et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis Am J Gastroenterol 92 1997 1867.
176. Marteau P., Probert CS., Lindgren S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate ulcerative colitis: A randomised, double blind, placebo controlled study Gut 54 2005 960.
177. Danish 5-ASA Group Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis: A randomized, double-blind multicenter trial Dig Dis Sci 32 1987 598.
178. Campieri M., Paoluzi P., d’Albasio G., et al. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis: A multicenter comparative trial with 5-ASA enema Dig Dis Sci 38 1993 1843.
179. Andreoli A., Spinella S., Levenstein S., et al. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis Ital J Gastroenterol 26 1994 121.
180. d’Albasio G., Pacini F., Camarri E., et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: A randomized double-blind study Am J Gastroenterol 92 1997 1143.
181. Lennard-Jones JE., Longmore AJ., Newell AC An assessment of prednisone, salazopyrine, and topical hydrocortisone used as outpatient treatment for ulcerative colitis Gut 1 1960 217.
182. Baron JH., Connell AM., Kanaghinis TG., et al. Outpatient treatment of ulcerative colitis. Comparison between three doses of oral prednisone BMJ 5302 1962 441.
183. Truelove SC., Jewell DP Intensive intravenous regimen for severe attacks of ulcerative colitis Lancet 1 1974 1067.
184. Truelove SC., Willoughby CP., Lee EG., Kettlewell MG Further experience in the treatment of severe attacks of ulcerative colitis Lancet 2 1978 1086.
185. Jarnerot G., Rolny P., Sandberg-Gertzen H Intensive intravenous treatment of ulcerative colitis Gastroenterol 89 1985 1005.
186. Kaplan HP., Portnoy B., Binder HJ., et al. A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis Gastroenterology 69 1975 91.
187. Meyers S., Sachar DB., Goldberg JD., et al. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis: A prospective, randomized, double-blind clinical trial Gastroenterology 85 1983 351.
188. Kornbluth A., Marion JF., Salomon P., et al. How effective is current medical therapy for severe ulcerative and Crohn’s colitis? An analytic review of selected trials J Clin Gastroenterol 20 1995 280.
189. Thalen BA., Axelsson BI., Andersson PH., et al. 6α-Fluoro-and 6α, 9α-difluoro-11β, 21-dihydroxy-16α, 17α-propylmethylenedioxypregn-4-ene-3, 20-dione: Synthesis and evaluation of activity and kinetics of their C-22 epimers Steroids 63 1998 37.
190. Keller R., Stoll R., Foerster EC., et al. Oral budesonide therapy for steroid-dependent ulcerative colitis: A pilot trial Aliment Pharmacol Ther 11 1997 1047.
191. Lofberg R., Danielsson A., Suhr O., et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis Gastroenterology 110 1996 1713.
192. Truelove SC Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: A report on a controlled therapeutic trial BMJ 2 1958 1072.
193. Watkinson G Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium BMJ 2 1958 1077.
194. Mulder CJ., Fockens P., Meijer JW., et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis Eur J Gastroenterol Hepatol 8 1996 549.
195. Hanauer SB., Robinson M., Pruitt R., et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study. U.S. Budesonide Enema Study Group Gastroenterology 115 1998 525.
196. Danish Budesonide Study Group Budesonide enema in distal ulcerative colitis: A randomized dose-response trial with prednisolone enema as positive control Scand J Gastroenterol 26 1991 1225.
197. Danielsson A., Hellers G., Lyrenas E., et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis Scand J Gastroenterol 22 1987 987.
198. Lofberg R., Ostergaard TO., Langholz E., et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis Aliment Pharmacol Ther 8 1994 623.
199. Lemann M., Galian A., Rutgeerts P., et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis Aliment Pharmacol Ther 9 1995 557.
200. Lindgren S., Lofberg R., Bergholm L., et al. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis Scand J Gastroenterol 37 2002 705.
201. Bar-Meir S., Fidder HH., Faszczyk M., et al. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis Dis Colon Rectum 46 2003 929.
202. Weinshilboum RM., Sladek SL Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity Am J Hum Genet 32 1980 651.
203. Jewell DP., Truelove SC Azathioprine in ulcerative colitis: Final report on controlled therapeutic trial BMJ 4 1974 627.
204. Caprilli R., Carratu R., Babbini M Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis: Preliminary report Am J Dig Dis 20 1975 115.
205. Kirk AP., Lennard-Jones JE Controlled trial of azathioprine in chronic ulcerative colitis BMJ 284 1982 1291.
206. Ardizzone S., Maconi G., Russo A Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis Gut 55 2006 47.
207. Rosenberg JL., Wall AJ., Levin B., et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis Gastroenterology 69 1975 96.
208. Hawthorne AB., Logan RF., Hawkey CJ., et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis BMJ 305 1992 20.
209. Sood A., Midha V., Sood N., et al. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis Indian J Gastroenterol 22 2003 79.
210. Sandborn WJ A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate Am J Gastroenterol 91 1996 423.
211. Colonna T., Korelitz BI The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn’s disease Am J Gastroenterol 89 1994 362.
212. Markowitz J., Grancher K., Mandel F., et al. Relationship of leukopenia to 6-MP induced remission of Crohn’s disease [abstract] J Pediatr Gastroenterol Nutr 27 1998 A8.
213. Dubinsky MC., Lamothe S., Yang HY., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Gastroenterology 118 2000 705.
214. Sandborn WJ., Tremaine WJ., Wolf DC., et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. North American Azathioprine Study Group Gastroenterology 117 1999 527.
215. Osterman MT., Kundu R., Lichtenstein GR., et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-analysis Gastroenterology 130 2006 1047.
216. Lennard L., Van Loon JA., Weinshilboum RM Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism Clin Pharmacol Ther 46 1989 149.
217. Colombel JF., Ferrari N., Debuysere H., et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy Gastroenterology 118 2000 1025.
218. Dubinsky MC., Reyes E., Ofman J., et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine Am J Gastroenterol 100 2005 2239.
219. Priest VL., Begg EJ., Gardiner SJ., et al. Pharmacoeconomic analyses of azathioprine, methotrexate, and prospective pharmacogenetic testing for the management of inflammatory bowel disease Pharmacoeconomics 24 2006 767.
220. Ardizzone S., Molteni P., Imbesi V., et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis J Clin Gastroenterol 25 1997 330.
221. Steinhart AH., Baker JP., Brzezinski A., et al. Azathioprine therapy in chronic ulcerative colitis J Clin Gastroenterol 12 1990 271.
222. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 2000; CD000545.
223. Kim PS., Zlatanic J., Korelitz BI., et al. Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease Am J Gastroenterol 94 1999 3254.
224. Fraser AG., Orchard TR., Jewell DP The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30-year review Gut 50 2002 485.
225. Connell WR., Kamm MA., Ritchie JK., et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: Twenty-seven years of experience Gut 34 1993 1081.
226. Su CG., Stein RB., Lewis JD., et al. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: Do risks outweigh benefits? Dig Liver Dis 32 2000 518.
227. Present DH., Meltzer SJ., Krumholz MP., et al. 6-Mercaptopurine in the management of inflammatory bowel disease: Short-and long-term toxicity Ann Intern Med 111 1989 641.
228. Lewis LD., Benin A., Szumlanski CL., et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction Clin Pharmacol Ther 62 1997 464.
229. Lowry PW., Szumlanski CL., Weinshilboum RM., et al. Balsalazide and azathioprine or 6-mercaptopurine: Evidence for a potentially serious drug interaction Gastroenterology 116 1999 1505.
230. Szumlanski CL., Weinshilboum RM Sulphasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine Br J Clin Pharmacol 39 1995 456.
231. Korelitz BI., Zlatanic J., Goel F., et al. Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease J Clin Gastroenterol 28 1999 341.
232. Cheng BK., Lichtenstein GR Are individuals with Crohn’s disease who are intolerant to 6-mercaptopurine able to tolerate azathioprine? [abstract] Gastroenterology 118 2000 A1336.
233. Warman JI., Korelitz BI., Fleisher MR., et al. Cumulative experience with short-and long-term toxicity to 6-mercaptopurine in the treatment of Crohn’s disease and ulcerative colitis J Clin Gastroenterol 37 2003 220.
234. Haber CJ., Meltzer SJ., Present DH., et al. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease Gastroenterology 91 1986 982.
235. Bouhnik Y., Lemann M., Mary JY., et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine Lancet 347 1996 215.
236. Kandiel A., Fraser AG., Korelitz BI., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine Gut 54 2005 1121.
237. Dayharsh GA., Loftus EV Jr., Sandborn WJ., et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine Gastroenterology 122 2002 72.
238. Lichtiger S., Present DH., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 330 1994 1841.
239. D’Haens G., Lemmens L., Geboes K., et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis Gastroenterology 120 2001 1323.
240. Cohen RD., Stein R., Hanauer SB Intravenous cyclosporin in ulcerative colitis: A five-year experience Am J Gastroenterol 94 1999 1587.
241. Fernandez-Banares F., Bertran X., Esteve-Comas M., et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis Am J Gastroenterol 91 1996 2498.
242. Moskovitz DN., Van Assche G., Maenhout B., et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis Clin Gastroenterol Hepatol 4 2006 760.
243. Van Assche G., D’Haens G., Noman M., et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis Gastroenterology 125 2003 1025.
244. Sternthal M., Murphy SJ., George J., et al. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease Am J Gastroenterol 103 2008 937.
245. Oren R., Arber N., Odes S., et al. Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial Gastroenterology 110 1996 1416.
246. Orth T., Peters M., Schlaak JF., et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: A 12-month pilot study Am J Gastroenterol 95 2000 1201.
247. Ford AC., Towler RJ., Moayyedi P., et al. Mycophenolate mofetil in refractory inflammatory bowel disease Aliment Pharmacol Ther 17 2003 1365.
248. Fellermann K., Steffen M., Stein J., et al. Mycophenolate mofetil: Lack of efficacy in chronic active inflammatory bowel disease Aliment Pharmacol Ther 14 2000 171.
249. Ogata H., Matsui T., Nakamura M., et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis Gut 55 2006 1255.
250. Fellermann K., Tanko Z., Herrlinger KR., et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506) Inflamm Bowel Dis 8 2002 317.
251. Hogenauer C., Wenzl HH., Hinterleitner TA., et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis Aliment Pharmacol Ther 18 2003 415.
252. Davies PS., Rhodes J., Heatley RV., et al. Metronidazole in the treatment of chronic proctitis: A controlled trial Gut 18 1977 680.
253. Gilat T., Suissa A., Leichtman G., et al. A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial J Clin Gastroenterol 9 1987 415.
254. Mantzaris GJ., Archavlis E., Christoforidis P., et al. A prospective, randomized, controlled trial of oral ciprofloxacin in acute ulcerative colitis Am J Gastroenterol 92 1997 454.
255. Mantzaris GJ., Hatzis A., Kontogiannis P., et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis Am J Gastroenterol 89 1994 43.
256. Chapman RW., Selby WS., Jewell DP Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis Gut 27 1986 1210.
257. Burke DA., Axon AT., Clayden SA., et al. The efficacy of tobramycin in the treatment of ulcerative colitis Aliment Pharmacol Ther 4 1990 123.
258. Turunen UM., Farkkila MA., Hakala K., et al. Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective, double-blind, placebo-controlled study Gastroenterology 115 1998 1072.
259. Fuller R Probiotics in man and animals J Appl Bacteriol 66 1989 365.
260. Bouhnik Y., Raskine L., Simoneau G., et al. The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: A double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study Am J Clin Nutr 80 2004 1658.
261. Langlands SJ., Hopkins MJ., Coleman N., et al. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel Gut 53 2004 1610.
262. Tursi A., Brandimarte G., Giorgetti GM., et al. Low dose balsalazide plus a high potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis Med Sci Monit 10 2004 126.
263. Kato K., Mizuno S., Umesaki Y., et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis Aliment Pharmacol Ther 20 2004 1133.
264. Rembacken BJ., Snelling AM., Hawkey PM., et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial Lancet 354 1999 635.
265. Furrie E., Macfarlane S., Kennedy A., et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial Gut 54 2005 242.
266. Cui HH., Chen CL., Wang JD., et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis World J Gastroenterol 10 2004 1521.
267. Ishikawa H., Akedo I., Umesaki Y., et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis J Am Coll Nutr 22 2003 56.
268. Kruis W., Schutz E., Fric P., et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis Aliment Pharmacol Ther 11 1997 853.
269. Kruis W., Fric P., Pokrotnieks J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine Gut 53 2004 1617.
270. Zocco MA., dal Verme LZ., Cremonini F., et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis Aliment Pharmacol Ther 23 2006 1567.
271. Guslandi M., Giollo P., Testoni PA A pilot trial of Saccharomyces boulardii in ulcerative colitis Eur J Gastroenterol Hepatol 15 2003 697.
272. Summers RW., Elliott DE., Urban JF., et al. Trichuris suis therapy for active ulcerative colitis: A randomized controlled trial Gastroenterology 128 2005 825.
273. Scheppach W Treatment of distal ulcerative colitis with short-chain fatty acid enemas: A placebo-controlled trial. German-Austrian SCFA Study Group Dig Dis Sci 41 1996 2254.
274. Vernia P., Marcheggiano A., Caprilli R., et al. Short-chain fatty acid topical treatment in distal ulcerative colitis Aliment Pharmacol Ther 9 1995 309.
275. Scheppach W., Sommer H., Kirchner T., et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis Gastroenterology 103 1992 51.
276. Empey LR., Jewell LD., Garg ML., et al. Fish oil-enriched diet is mucosal protective against acetic acid-induced colitis in rats Can J Physiol Pharmacol 69 1991 480.
277. Marotta F., Chui DH., Safran P., et al. Shark fin enriched diet prevents mucosal lipid abnormalities in experimental acute colitis Digestion 56 1995 46.
278. Nieto N., Torres MI., Rios A., et al. Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis J Nutr 132 2002 11.
279. Aslan A., Triadafilopoulos G Fish oil fatty acid supplementation in active ulcerative colitis: A double-blind, placebo-controlled, crossover study Am J Gastroenterol 87 1992 432.
280. Lorenz R., Weber PC., Szimnau P., et al. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease: A randomized, placebo-controlled, double-blind cross-over trial J Intern Med 225 Suppl 1989 225.
281. Hawthorne AB., Daneshmend TK., Hawkey CJ., et al. Treatment of ulcerative colitis with fish oil supplementation: A prospective 12-month randomised controlled trial Gut 33 1992 922.
282. Greenfield SM., Green AT., Teare JP., et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis Aliment Pharmacol Ther 7 1993 159.
283. McIntyre PB., Powell-Tuck J., Wood SR., et al. Controlled trial of bowel rest in the treatment of severe acute colitis Gut 27 1986 481.
284. Dickinson RJ., Ashton MG., Axon AT., et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis Gastroenterology 79 1980 1199.
285. Sandborn WJ., Tremaine WJ., Offord KP., et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: A randomized, double-blind, placebo-controlled trial Ann Intern Med 126 1997 364.
286. Pullan RD., Rhodes J., Ganesh S., et al. Transdermal nicotine for active ulcerative colitis N Engl J Med 330 1994 811.
287. Guslandi M., Frego R., Viale E., et al. Distal ulcerative colitis refractory to rectal mesalamine: Role of transdermal nicotine versus oral mesalamine Can J Gastroenterol 16 2002 293.
288. Sandborn WJ Nicotine therapy for ulcerative colitis: A review of rationale, mechanisms, pharmacology, and clinical results Am J Gastroenterol 94 1999 1161.
289. Thomas GA., Rhodes J., Ragunath K., et al. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis Eur J Gastroenterol Hepatol 8 1996 769.
290. Green JT., Thomas GA., Rhodes J., et al. Nicotine enemas for active ulcerative colitis: A pilot study Aliment Pharmacol Ther 11 1997 859.
291. Sandborn WJ., Tremaine WJ., Leighton JA., et al. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: A pilot study Aliment Pharmacol Ther 11 1997 663.
292. Thomas GA., Rhodes J., Mani V., et al. Transdermal nicotine as maintenance therapy for ulcerative colitis N Engl J Med 332 1995 988.
293. Evans RC., Wong VS., Morris AI., et al. Treatment of corticosteroid-resistant ulcerative colitis with heparin: A report of 16 cases Aliment Pharmacol Ther 11 1997 1037.
294. Folwaczny C., Wiebecke B., Loeschke K Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease Am J Gastroenterol 94 1999 1551.
295. Ang YS., Mahmud N., White B., et al. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease Aliment Pharmacol Ther 14 2000 1015.
296. Panes J., Esteve M., Cabre E., et al. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis Gastroenterology 119 2000 903.
297. Torkvist L., Thorlacius H., Sjoqvist U., et al. Low-molecular-weight heparin as adjuvant therapy in active ulcerative colitis Aliment Pharmacol Ther 13 1999 1323.
298. Vrij AA., Jansen JM., Schoon EJ., et al. Low-molecular-weight heparin treatment in steroid-refractory ulcerative colitis: Clinical outcome and influence on mucosal capillary thrombi Scand J Gastroenterol Suppl 234 2001 41.
299. Bloom S., Kiilerich S., Lassen MR., et al. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis Aliment Pharmacol Ther 19 2004 871.
300. Siegel SA., Shealy DJ., Nakada MT., et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo Cytokine 7 1995 15.
301. Knight DM., Trinh H., Le J., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Mol Immunol 30 1993 1443.
302. Scallon BJ., Moore MA., Trinh H., et al. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions Cytokine 7 1995 251.
303. van Deventer SJ Review article: Targeting TNF-α as a key cytokine in the inflammatory processes of Crohn’s disease-the mechanisms of action of infliximab Aliment Pharmacol Ther 13 Suppl 4 1999 3-8.
304. Lugering A., Schmidt M., Lugering N., et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway Gastroenterology 121 2001 1145.
305. Rutgeerts P., Sandborn WJ., Feagan BG., et al. Infliximab for induction and maintenance therapy for ulcerative colitis N Engl Med J 353 2005 2462.
306. 4 integrin Aliment Pharmacol Ther 16 2002 699.
307. 7 integrin N Engl J Med 352 2005 2499.
308. Van Assche G., Dalle I., Noman M., et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis Am J Gastroenterol 98 2003 369.
309. Creed TJ., Norman MR., Probert CS., et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis Aliment Pharmacol Ther 18 2003 65.
310. Plevy S., Salzberg B., Van Assche G., et al. A phase I study of visilzumab, a humanized anti-CD3 monoclonal antibody in severe steroid-refractory ulcerative colitis Gastroenterology 133 2007 1414.
311. Sinha A., Nightingale J., West KP., et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis N Engl J Med 349 2003 350.
312. Sandborn WJ., Sands BE., Wolf DC., et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: A randomized, double-blind, placebo-controlled, dose-escalation trial Aliment Pharmacol Ther 17 2003 1355.
313. Sasaki M., Tsujikawa T., Fujiyama Y., et al. Leukocytapheresis therapy for severe ulcerative colitis Ther Apheresis 2 1998 101.
314. Sawada K., Ohnishi K., Fukui S., et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease J Gastroenterol 30 1995 322.
315. Shimoyama T., Sawada K., Hiwatashi N., et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: A multicenter study J Clin Apher 16 2001 1.
316. Kohgo Y., Hibi H., Chiba T., et al. Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis: A multicenter open label trial Ther Apher 6 2002 255.
317. Hanai H., Watanabe F., Takeuchi K., et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: A prospective, uncontrolled, pilot study Clin Gastroenterol Hepatol 1 2003 28.
318. Naganuma M., Funakoshi S., Sakuraba A., et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis Inflamm Bowel Dis 10 2004 251.
319. Suzuki Y., Yoshimura N., Saniabadi AR., et al. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study Dig Dis Sci 49 2004 565.
320. Sawada K., Muto T., Shimoyama T., et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column Curr Pharm Des 9 2003 307.
321. Sands BE., Sandborn WJ., Feagan B., et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis Gastroenterology 135 2008 400.
322. Katayama K., Wada K., Nakajima A., et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model Gastroenterology 124 2003 1315.
323. Tanaka T., Kohno H., Yoshitani S., et al. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats Cancer Res 61 2001 2424.
324. Saubermann LJ., Nakajima A., Wada K., et al. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis Inflamm Bowel Dis 8 2002 330.
325. Desreumaux P., Dubuquoy L., Nutten S., et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARγ) heterodimer: A basis for new therapeutic strategies J Exp Med 193 2001 827.
326. Lewis JD., Lichtenstein GR., Deren JJ., et al. Rosiglitazone for active ulcerative colitis: A randomized placebo-controlled trial Gastroenterology 134 2008 688.
327. Myrvold HE The continent ileostomy World J Surg 11 1987 720.
328. Penna C., Daude F., Parc R., et al. Previous subtotal colectomy with ileostomy and sigmoidostomy improves the morbidity and early functional results after ileal pouch-anal anastomosis in ulcerative colitis Dis Colon Rectum 36 1993 343.
329. Fazio VW., Ziv Y., Church JM., et al. Ileal pouch-anal anastomoses complications and function in 1005 patients Ann Surg 222 1995 120.
330. Hahnloser D., Pemberton JH., Wolff BG., et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis Br J Surg 94 2007 333.
331. Larson DW., Cima RR., Dozois EJ., et al. Safety, feasibility, and short-term outcomes of laparoscopic ileal-pouch-anal anastomosis: A single institutional case-matched series Ann Surg 243 2006 667.
332. Larson DW., Davies MM., Dozois EJ., et al. Sexual function, body image, and quality of life after laparoscopic and open ileal pouch-anal anastomosis Dis Colon Rectum 51 2008 392.
333. Maartense S., Dunker MS., Slors JF., et al. Hand-assisted laparoscopic versus open restorative proctocolectomy with ileal pouch anal anastomosis: A randomized trial Ann Surg 240 2004 984.
334. Lennard-Jones JE., Ritchie JK., Hilder W., et al. Assessment of severity in colitis: a preliminary study Gut 16 1975 579.
335. Bartram CI Radiology in the current assessment of ulcerative colitis Gastrointest Radiol 1 1977 383.
336. Roys G., Kaplan MS., Juler GL Surgical management of toxic megacolon Am J Gastroenterol 68 1977 161.
337. Hartong WA., Arvanitakis C., Skibba RM., et al. Treatment of toxic megacolon: A comparative review of 29 patients Am J Dig Dis 22 1977 195.
338. Marion JF., Present DH The modern medical management of acute, severe, ulcerative colitis Eur J Gastroenterol Hepatol 9 1997 831.
339. Panos MZ., Wood MJ., Asquith P Toxic megacolon: The knee-elbow position relieves bowel distention Gut 34 1993 1726.
340. Strauss RJ., Flint GW., Platt N., et al. The surgical management of toxic dilatation of the colon: A report of 28 cases and review of the literature Ann Surg 184 1976 682.
341. Greenstein AJ., Aufses AH Jr Differences in pathogenesis, incidence, and outcome of perforation in inflammatory bowel disease Surg Gynecol Obstet 160 1985 63.
342. Greenstein AJ., Sachar DB., Gibas A., et al. Outcome of toxic dilatation in ulcerative and Crohn’s colitis J Clin Gastroenterol 7 1985 137.
343. Grant CS., Dozois RR Toxic megacolon: Ultimate fate of patients after successful medical management Am J Surg 147 1984 106.
344. Greenstein AJ., Barth JA., Sachar DB., et al. Free colonic perforation without dilatation in ulcerative colitis Am J Surg 152 1986 272.
345. Gumaste V., Sachar DB., Greenstein AJ Benign and malignant colorectal strictures in ulcerative colitis Gut 33 1992 938.
346. Reiser JR., Waye JD., Janowitz HD., et al. Adenocarcinoma in strictures of ulcerative colitis without antecedent dysplasia by colonoscopy Am J Gastroenterol 89 1994 119.
347. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis Gastroenterology 126 2004 451.
348. Brentnall TA., Haggitt RC., Rabinovitch PS., et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis Gastroenterology 110 1996 331.
349. Askling J., Dickman PW., Karlen P., et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease Gastroenterology 120 2001 1356.
350. Heuschen UA., Hinz U., Allemeyer EH., et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis Gastroenterology 120 2001 841.
351. Velayos FS., Loftus EV., Jess T., et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study Gastroenterology 130 2006 1941.
352. Itzkowitz SH., Harpaz N Diagnosis and management of dysplasia in patients with inflammatory bowel disease Gastroenterology 126 2004 1634.
353. Lewis JD., Deren JJ., Lichtenstein GR Cancer risk in patients with inflammatory bowel disease Gastroenterol Clin North Am 28 1999 459.
354. Riddell RH., Goldman H., Ransohoff DF., et al. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications Hum Pathol 14 1983 931.
355. Rutter MD., Saunders BP., Wilkinson KH., et al. Most dysplasia in ulcerative colitis is visible at colonoscopy Gastrointest Endosc 60 2004 334.
356. Rubin DT., Rothe JA., Hetzel JT., et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 65 2007 998.
357. Blonski W., Kundu R., Lewis J., et al. Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis? Scand J Gastroenterol 43 2008 698.
358. Blackstone MO., Riddell RH., Rogers BH., et al. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy Gastroenterology 80 1981 366.
359. Butt JH., Konishi F., Morson BC., et al. Macroscopic lesions in dysplasia and carcinoma complicating ulcerative colitis Dig Dis Sci 28 1983 18.
360. Lennard-Jones JE., Melville DM., Morson BC., et al. Precancer and cancer in extensive ulcerative colitis: Findings among 401 patients over 22 years Gut 31 1990 800.
361. Rosenstock E., Farmer RG., Petras R., et al. Surveillance for colonic carcinoma in ulcerative colitis Gastroenterology 89 1985 1342.
362. Bernstein CN., Shanahan F., Weinstein WM Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 343 1994 71.
363. Nugent FW., Haggitt RC., Gilpin PA Cancer surveillance in ulcerative colitis Gastroenterology 100 1991 1241.
364. Medlicott SA., Jewell LD., Price L., et al. Conservative management of small adenomata in ulcerative colitis Am J Gastroenterol 92 1997 2094.
365. Connell WR., Lennard-Jones JE., Williams CB., et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis Gastroenterology 107 1994 934.
366. Engelsgjerd M., Farraye FA., Odze RD Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis Gastroenterology 117 1999 1288.
367. Rubin PH., Friedman S., Harpaz N., et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps Gastroenterology 117 1999 1295.
368. Ullman T., Croog V., Harpaz N., et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis Gastroenterology 125 2003 1311.
369. Befrits R., Ljung T., Jaramillo E., et al. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: A follow-up study Dis Colon Rectum 45 2002 615.
370. Lim CH., Dixon MF., Vail A., et al. Ten-year follow-up of ulcerative colitis patients with and without low-grade dysplasia Gut 52 2003 1127.
371. Thomas T., Abrams KA., Robinson RJ., et al. Meta-analysis: Cancer risk of low-grade dysplasia in chronic ulcerative colitis Aliment Pharmacol Ther 25 2007 657.
372. Kornbluth A., Sachar DB Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee Am J Gastroenterol 92 1997 204.
373. Winawer S., Fletcher R., Rex D., et al. Colorectal cancer screening and surveillance: Clinical guidelines and rationale-update based on new evidence Gastroenterology 124 2003 544.
374. Rubin CE., Haggitt RC., Burmer GC., et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis Gastroenterology 103 1992 1611.
375. Bernstein CN., Weinstein WM., Levine DS., et al. Physicians’ perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis Am J Gastroenterol 90 1995 2106.
376. Eaden JA., Ward BA., Mayberry JF How gastroenterologists screen for colon cancer in ulcerative colitis: An analysis of performance Gastrointest Endosc 51 2000 123.
377. Judge TA., Lewis JD., Lichtenstein GR Colonic dysplasia and cancer in inflammatory bowel disease Gastrointest Endosc Clin North Am 12 2002 495.
378. Bernstein CN ALMs versus DALMs in ulcerative colitis: Polypectomy or colectomy? Gastroenterology 117 1999 1488.
379. Kiesslich R., Fritsch J., Holtmann M., et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis Gastroenterology 124 2003 880.
380. Jaramillo E., Watanabe M., Befrits R., et al. Small, flat colorectal neoplasias in long-standing ulcerative colitis detected by high-resolution electronic video endoscopy Gastrointest Endosc 44 1996 15.
381. Rutter MD., Saunders BP., Schofield G., et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis Gut 53 2004 256.
382. Matsumoto T., Kudo T., Jo Y., et al. Magnifying colonoscopy with narrow band imaging system for the diagnosis of dysplasia in ulcerative colitis: A pilot study Gastrointest Endosc 66 2007 957.
383. Dekker E., van den Broek FJC., Reitsma JB., et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with long-standing ulcerative colitis Endoscopy 39 2007 216.
384. Vogelstein B., Fearon ER., Hamilton SR., et al. Genetic alterations during colorectal-tumor development N Engl J Med 319 1988 525.
385. Itzkowitz SH., Young E., Dubois D., et al. Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: A retrospective case-control study Gastroenterology 110 1996 694.
386. Karlen P., Young E., Brostrom O., et al. Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: Relation to dysplasia and DNA aneuploidy Gastroenterology 115 1998 1395.
387. Benhattar J., Saraga E Molecular genetics of dysplasia in ulcerative colitis Eur J Cancer 31A 1995 1171.
388. Odze RD., Brown CA., Hartmann CJ., et al. Genetic alterations in chronic ulcerative colitis-associated adenoma-like DALMs are similar to non-colitic sporadic adenomas Am J Surg Pathol 24 2000 1209.
389. Fogt F., Vortmeyer AO., Stolte M., et al. Loss of heterozygosity of the von Hippel-Lindau gene locus in polypoid dysplasia but not flat dysplasia in ulcerative colitis or sporadic adenomas Hum Pathol 29 1998 961.
390. Fogt F., Vortmeyer AO., Goldman H., et al. Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma Hum Pathol 29 1998 131.
391. Walsh SV., Loda M., Torres CM., et al. P53 and beta catenin expression in chronic ulcerative colitis-associated polypoid dysplasia and sporadic adenomas: An immunohistochemical study Am J Surg Pathol 23 1999 963.
392. Harpaz N., Peck AL., Yin J., et al. p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma Hum Pathol 25 1994 1069.
393. Lashner BA., Heidenreich PA., Su GL., et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis Gastroenterology 97 1989 255.
394. Lashner BA., Provencher KS., Seidner DL., et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis Gastroenterology 112 1997 29.
395. Velayos FS., Terdiman JP., Walsh JM Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: A systematic review and metaanalysis of observational studies Am J Gastroenterol 100 2005 1345.
396. Tung BY., Emond MJ., Haggitt RC., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis Ann Intern Med 134 2001 89.
397. Pardi DS., Loftus EV Jr., Kremers WK., et al. Ursodeoxycholic acid as a chemoprotective agent in patients with ulcerative colitis and primary sclerosing cholangitis Gastroenterology 124 2003 889.
398. Scarpa M., van Koperen PJ., Ubbink DT., et al. Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis Br J Surg 94 2007 534.
399. Das P., Johnson MW., Tekkis PP., et al. Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis Colorectal Dis 9 2007 15.
400. Dozois RR., Goldberg SM., Rothenberger DA., et al. Restorative proctocolectomy with ileal reservoir Int J Colorectal Dis 1 1986 2.
401. Stahlberg D., Gullberg K., Liljeqvist L., et al. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors Dis Colon Rectum 39 1996 1012.
402. Nicholls RJ., Banerjee AK Pouchitis: Risk factors, etiology, and treatment World J Surg 22 1998 347.
403. Sandborn WJ Pouchitis following ileal pouch-anal anastomosis: Definition, pathogenesis, and treatment Gastroenterology 107 1994 1856.
404. Hurst RD., Molinari M., Chung TP., et al. Prospective study of the incidence, timing, and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy Arch Surg 131 1996 497.
405. Mahadevan U., Sandborn WJ Diagnosis and management of pouchitis Gastroenterology 124 2003 1636.
406. Shepherd NA., Hulten L., Tytgat GNJ., et al. Workshop: Pouchitis Int J Coloectal Dis 4 1989 205.
407. Sandborn WJ., Tremaine WJ., Batts KP., et al. Fecal bile acids, short chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis Dig Dis Sci 40 1995 1474.
408. Achkar JP., Al-Hadad M., Lashner B., et al. Differentiating risk factors for acute and chronic pouchitis Clin Gastroenterol Hepatol 3 2005 60.
409. Fleshner P., Ippoliti A., Dubinsky M., et al. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis Clin Gastroenterol Hepatol 5 2007 952.
410. Hui T., Landers C., Vasiliauskas EA., et al. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation Dis Colon Rectum 48 2005 1254.
411. Madden MV., McIntyre AS., Nicholls RJ Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis Dig Dis Sci 39 1994 1193.
412. Shen B., Achkar JP., Lashner BA., et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis Inflamm Bowel Dis 7 2001 301.
413. Nygaard K., Bergan T., Bjorneklett A., et al. Topical metronidazole treatment in pouchitis Scand J Gastroenterol 29 1994 462.
414. Gionchetti P., Rizzello F., Venturi A., et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis Aliment Pharmacol Ther 13 1999 713.
415. Mimura T., Rizzello F., Helwig U., et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis Aliment Pharmacol Ther 16 2002 909.
416. Abdelrazeq AS., Kelly SM., Lund JN., et al. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis Colorectal Dis 7 2005 182.
417. Shen B., Fazio VW., Remzi FH., et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis Dis Colon Rectum 50 2007 498.
418. Gionchetti P., Amadini C., Rizzello F., et al. Review article: Treatment of mild to moderate ulcerative colitis and pouchitis Aliment Pharmacol Ther 16 Suppl 4 2002 13.
419. Sambuelli A., Boerr L., Negreira S., et al. Budesonide enema in pouchitis: A double-blind, double-dummy, controlled trial Aliment Pharmacol Ther 16 2002 27.
420. Gionchetti P., Rizzello F., Poggioli G., et al. Oral budesonide in the treatment of chronic refractory pouchitis Aliment Pharmacol Ther 25 2007 1231.
421. Winter TA., Dalton HR., Merrett MN., et al. Cyclosporin A retention enemas in refractory distal ulcerative colitis and “pouchitis.” Scand J Gastroenterol 28 1993 701.
422. Calabrese C., Gionchetti P., Rizzello F., et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis Aliment Pharmacol Ther 27 2008 759.
423. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacterio-therapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial Gastroenterology 119 2000 305.
424. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial Gastroenterology 124 2003 1202.
425. Mimura T., Rizzello F., Helwig U., et al. Once-daily high-dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis Gut 53 2004 108.
426. Shen B., Brzezinski A., Fazio VW., et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: Experience in a clinical practice Aliment Pharmacol Ther 22 2005 721.
427. Welters CF., Heineman E., Thunnissen FB., et al. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis Dis Colon Rectum 45 2002 621.
428. Friedman G., George J Treatment of refractory pouchitis with prebiotic and probiotic therapy Gastroenterology 118 2000 G4167.
429. Gionchetti P., Rizzello F., Venturi A., et al. Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis Aliment Pharmacol Ther 11 1997 673.
430. Tremaine WJ., Sandborn WJ., Wolff BG., et al. Bismuth carbomer foam enemas for active chronic pouchitis: A randomized, double-blind, placebo-controlled trial Aliment Pharmacol Ther 11 1997 1041.
431. Tremaine W., Sandborn W., Kenan ML Bismuth subsalicylate tablets for chronic antibiotic-resistant pouchitis [abstract] Gastroenterology 114 1998 A1101.
432. Wischmeyer P., Pemberton JH., Phillips SF Chronic pouchitis after ileal pouch-anal anastomosis: Responses to butyrate and glutamine suppositories in a pilot study Mayo Clin Proc 68 1993 978.
433. Kuhbacher T., Schreiber S., Runkel N Pouchitis: Pathophysiology and treatment Int J Colorectal Dis 13 1998 196.
434. Finkel SI., Janowitz HD Trauma and the pyoderma gangrenosum of inflammatory bowel disease Gut 22 1981 410.
435. Callen JP Pyoderma gangrenosum Lancet 351 1998 581.
436. Powell RJ., Holbrook MR., Stevens A Pyoderma gangrenosum and its treatment Lancet 350 1997 1720.
437. Lyon CC., Stapleton M., Smith AJ., et al. Topical tacrolimus in the management of peristomal pyoderma gangrenosum J Dermatol Treat 12 2001 13.
438. Friedman S., Marion JF., Scherl E., et al. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease Inflamm Bowel Dis 7 2001 1.
439. Galun E., Flugelman MY., Rachmilewitz D Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and dapsone Am J Gastroenterol 81 1986 988.
440. Van Hale HM., Rogers RS III., Zone JJ., et al. Pyostomatitis vegetans: A reactive mucosal marker for inflammatory disease of the gut Arch Dermatol 121 1985 94.
441. Orchard TR., Wordsworth BP., Jewell DP Peripheral arthropathies in inflammatory bowel disease: Their articular distribution and natural history Gut 42 1998 387.
442. Braun J., Deodhar A., Dijkmans B., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period Arthritis Rheum 59 2008 1270.
443. Vakil N., Sparberg M Steroid-related osteonecrosis in inflammatory bowel disease Gastroenterology 96 1989 62.
444. Miehsler W., Reinisch W., Valic E., et al. Is inflammatory bowel disease an independent and disease-specific risk factor for thromboembolism? Gut 53 2004 542.
445. Talbot RW., Heppell J., Dozois RR., et al. Vascular complications of inflammatory bowel disease Mayo Clin Proc 61 1986 140.
446. Schapira M., Henrion J., Ravoet C., et al. Thromboembolism in inflammatory bowel disease Acta Gastroenterol Belg 62 1999 182.
447. Liebman HA., Kashani N., Sutherland D., et al. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease Gastroenterology 115 1998 830.
448. Papa A., Danese S., Grillo A., et al. Review article: Inherited thrombophilia in inflammatory bowel disease Am J Gastroenterol 98 2003 1247.
449. Guedon C., Cam-Duchez V., Lalaude O., et al. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease Am J Gastroenterol 96 2001 1448.
450. Greenstein AJ., Sachar DB., Panday AK., et al. Amyloidosis and inflammatory bowel disease: A 50-year experience with 25 patients Medicine (Baltimore) 71 1992 261.
451. Patwardhan RV., Heilpern RJ., Brewster AC., et al. Pleuropericarditis-an extraintestinal complication of inflammatory bowel disease: Report of three cases and review of literature Arch Intern Med 143 1983 94.
452. Rheingold OJ Inflammatory bowel disease and pericarditis [letter] Ann Intern Med 82 1975 592.
453. Mukhopadhyay D., Nasr K., Grossman BJ., et al. Pericarditis associated with inflammatory bowel disease JAMA 211 1970 1540.
454. Oxentenko AS., Loftus EV., Oh JK., et al. Constrictive pericarditis in chronic ulcerative colitis J Clin Gastroenterol 34 2002 247.
455. Gujral N., Friedenberg F., Friedenberg J., et al. Pleuropericarditis related to the use of mesalamine Dig Dis Sci 41 1996 624.
456. Ishikawa N., Imamura T., Nakajima K., et al. Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis Intern Med 40 2001 901.
457. Godet PG., Cowie R., Woodman RC., et al. Pulmonary function abnormalities in patients with ulcerative colitis Am J Gastroenterol 92 1997 1154.
458. McKee AL., Rajapaksa A., Kalish PE., et al. Severe interstitial pulmonary fibrosis in a patient with chronic ulcerative colitis Am J Gastroenterol 78 1983 86.
459. Forrest JA., Shearman DJ Pulmonary vasculitis and ulcerative colitis Am J Dig Dis 20 1975 482.
460. Mahadeva R., Walsh G., Flower CD., et al. Clinical and radiological characteristics of lung disease in inflammatory bowel disease Eur Respir J 15 2000 41.